Section Arrow
NRIX.NASDAQ
- Nurix Therapeutics
Quotes are at least 15-min delayed:2026/02/09 06:33 EST
Pre Market
Last
 --
-- (--)
Bid
16.56
Ask
18.53
High -- 
Low -- 
Volume -- 
Regular Hours (Closed)
Last
 16.85
+0.9 (+5.64%)
Day High 
17.03 
Prev. Close
15.95 
1-M High
20.18 
Volume 
836.57K 
Bid
16.56
Ask
18.53
Day Low
16.26 
Open
16.29 
1-M Low
15.87 
Market Cap 
1.64B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 17.51 
20-SMA 18.2 
50-SMA 18.34 
52-W High 22.4999 
52-W Low 8.18 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-3.05/-3.11
Enterprise Value
1.69B
Balance Sheet
Book Value Per Share
5.24
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
83.98M
Operating Revenue Per Share
0.67
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
LIMNLiminatus Pharma Inc1.84-0.21-10.24%-- 
Pre Market 1.72 -0.12 -6.52%
RXRXRecursion Pharmaceuticals3.98+0.42+11.80%-- 
Pre Market 4.01 +0.03 +0.75%
FOLDAmicus Therapeutics14.3+0.02+0.14%-- 
Pre Market 14.35 +0.05 +0.35%
ARWRArrowhead Pharmaceuticals64.52-0.12-0.19%-- 
Pre Market 64.19 -0.33 -0.51%
ROIVRoivant Sciences Ltd25.82+4.68+22.14%1.95PE
Pre Market 25.48 -0.34 -1.32%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.